- |||||||||| Review, Journal: Advancements in Diabetic Kidney Disease Management: Integrating Innovative Therapies and Targeted Drug Development. (Pubmed Central) - May 20, 2024
Emerging agents including GLP-1 agonists, anti-inflammatory agents like bardoxolone, and mineralocorticoid receptor antagonists show promise in mitigating DKD progression. Many novel therapies including monoclonal antibodies CSL346, Lixudebart, and tozorakimab, mesenchymal stem/stromal cell infusion, and cannabinoid-1 receptor inverse agonism via INV-202 are currently in clinical trials and present opportunities for further drug development.
- |||||||||| lixudebart (ALE.F02) / Alentis Therap
Enrollment change: Rescue of Nephrons With ALE.F02 (RENAL-F02) (clinicaltrials.gov) - May 10, 2024
P2, N=80, Recruiting,
Many novel therapies including monoclonal antibodies CSL346, Lixudebart, and tozorakimab, mesenchymal stem/stromal cell infusion, and cannabinoid-1 receptor inverse agonism via INV-202 are currently in clinical trials and present opportunities for further drug development. N=60 --> 80
- |||||||||| lixudebart (ALE.F02) / Alentis Therap
Expression of Exposed CLDN1 Is Linked to Early Pathological Lesions in Idiopathic Pulmonary Fibrosis (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_9063;
Exposed CLDN1 is present in areas of active matrix deposition, even in mild disease areas, suggesting a direct involvement of exposed CLDN1 in the maturation of the fibroblastic scars in IPF. Importantly, we provided a preclinical proof-of-concept for Lixudebart as a novel therapeutic approach based on the enrichment of exposed CLDN1 during disease progression and its association with epithelial injury and active fibrotic lesions in IPF lungs.
- |||||||||| lixudebart (ALE.F02) / Alentis Therap
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: FEGATO-01: A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis (clinicaltrials.gov) - Mar 13, 2024
P1, N=38, Recruiting,
Importantly, we provided a preclinical proof-of-concept for Lixudebart as a novel therapeutic approach based on the enrichment of exposed CLDN1 during disease progression and its association with epithelial injury and active fibrotic lesions in IPF lungs. Phase classification: P1b --> P1 | N=28 --> 38 | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
- |||||||||| lixudebart (ALE.F02) / Alentis Therap
Enrollment open: Rescue of Nephrons With ALE.F02 (RENAL-F02) (clinicaltrials.gov) - Oct 27, 2023
P2, N=60, Recruiting,
Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024 Not yet recruiting --> Recruiting
|
